DownRightNowNews
Trending
13 dead, dozens injured in bus- truck collision on Egypt's Assiut Western Desert RoadNeuroXT Inc. Receives U.S. FDA 510(k) Clearance for NEXT-Cue, AI Software Supporting Prognostic Assessment in Mild Cognitive ImpairmentAirbnb introduces weather protection that will pay out if it rains too much on your holidayWhy your Wi-Fi is strong in one room but weak in another, and how to fix itUAE digital IDs: Which documents can you add to your phone's wallet?Saudi Arabia braces for heavy thunderstorms, widespread rain until October 2813 dead, dozens injured in bus- truck collision on Egypt's Assiut Western Desert RoadNeuroXT Inc. Receives U.S. FDA 510(k) Clearance for NEXT-Cue, AI Software Supporting Prognostic Assessment in Mild Cognitive ImpairmentAirbnb introduces weather protection that will pay out if it rains too much on your holidayWhy your Wi-Fi is strong in one room but weak in another, and how to fix itUAE digital IDs: Which documents can you add to your phone's wallet?Saudi Arabia braces for heavy thunderstorms, widespread rain until October 28
Technology

tvOS 27 to add Siri AI for Apple TV 4K, per new leak

·19 Aug
Share:PostShare

Siri AI was unveiled in June for most Apple platforms—but Apple TV and HomePod missed out. A new leak, however, points to tvOS 27 including Siri AI after all.

9

9to5 Mac

Original source

Read full story
AutomotiveLifestyle

Related Stories

Technology1h ago

NeuroXT Inc. Receives U.S. FDA 510(k) Clearance for NEXT-Cue, AI Software Supporting Prognostic Assessment in Mild Cognitive Impairment

Supports clinicians in assessing progression from mild cognitive impairment to Alzheimer's dementia within five years NeuroXT Inc. to advance U.S. commercialization and adoption by healthcare institutions following FDA 510(k) clearance SEOUL, South Korea, Oct. 20, 2026 /PRNewswire/ -- NeuroXT Inc., a medical device manufacturer, announced that NEXT-Cue, its AI-based Software as a Medical Device (SaMD) supporting prognostic assessment in patients with mild cognitive impairment (MCI), has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) as a Class II medical device. NEXT-Cue supports clinicians in assessing patients with MCI who are being evaluated for progression to Alzheimer's dementia within five years. By integrating brain MRI images, demographic information, and cognitive assessment data, it provides supplementary information to support clinical assessment and individualized patient management planning. "Receiving FDA 510(k) clearance marks an important milestone in NeuroXT's entry into the U.S. healthcare market," said Joon-Kyung Seong, CEO of NeuroXT Inc. "Starting with NEXT-Cue, we plan to establish real-world clinical use cases at leading healthcare institutions across the United States and accelerate our commercialization efforts, with the broader goal of contributing to earlier diagnosis and appropriate treatment of Alzheimer's disease." NeuroXT Inc. is also pursuing regulatory authorization for NEXT-Cue from the Ministry of Food and Drug Safety (MFDS) in the Republic of Korea and plans to begin commercialization in the Korean market early next year. About NeuroXT Inc. NeuroXT Inc. is a medical AI company specializing in the development of AI-based imaging biomarkers for Alzheimer's disease. The company is developing AI technologies that primarily use MRI imaging to assess Alzheimer's disease-related pathology and potential treatment response. Through precision medicine solutions designed to help identify optimal treatment timing for individual patients, NeuroXT Inc. aims to advance the treatment of Alzheimer's disease.

PPr Newswire Apac

Headlines and briefs on this site are for information only. Always verify details on the original source or live status page.

Read Disclaimer